Skip to main content
CYCLOPHARM LIMITED logo

CYCLOPHARM LIMITED — Investor Relations & Filings

Ticker · CYC ISIN · AU000000CYC5 LEI · 9845008C9R4608FB7007 ASX Manufacturing
Open in API
Filings indexed 777 across all filing types
Latest filing 2008-01-24 Board/Management Inform…
Country AU Australia
Listing ASX CYC

About CYCLOPHARM LIMITED

https://www.cyclopharm.com.au

Cyclopharm Limited focuses on the development and commercialization of specialized medical imaging technologies. Its primary product, Technegas, is an ultra-fine dispersion of carbon nano-particles labeled with Technetium-99m, utilized for functional lung ventilation imaging. This technology is used to diagnose Pulmonary Embolism by providing high-resolution images via the inhalation of a radioactive aerosol. Technegas is generated on-site using proprietary equipment and is compatible with SPECT and SPECT/CT imaging. The system is engineered to provide diagnostic clarity even in patients with underlying airway diseases. Beyond its primary diagnostic use, the company investigates applications for its technology in managing chronic obstructive pulmonary disease (COPD), asthma, and lung cancer.

Recent filings

Filing Released Lang Actions
Director Appointment/Resignation 1 page ?Kb
Board/Management Information Classification · 100% confidence The document is a short announcement dated 25 January 2008, informing about the resignation of a director, Dr Bernard Salin, from Cyclopharm Limited. It thanks the director and mentions ongoing business relations but contains no financial data, no report, no voting results, or other regulatory filings. The content clearly fits the category of Board/Management Information, which covers announcements of changes in the company's board of directors or senior management. The document length is short (1017 characters), consistent with a brief management change notice rather than a full report or other filing type.
2008-01-24 English
Cyclopharm achieves a major milestone 1 page ?Kb
Regulatory Filings Classification · 95% confidence The document is a company announcement from Cyclopharm Limited dated 7 January 2008. It announces the finalization of an agreement to establish a commercial production site for PET radioisotopes and molecular imaging products. The content focuses on a business milestone and future plans rather than financial results, regulatory filings, or detailed financial data. The document is relatively short (2083 characters) and reads like a press release or business update rather than a formal financial report or regulatory filing. There is no indication of financial statements, audit information, management changes, or shareholder voting results. Therefore, it fits best under the category of a general regulatory announcement or business update. Given the options, the most appropriate classification is Regulatory Filings (RNS), which serves as a fallback for miscellaneous announcements that do not fit other categories.
2008-01-06 English
Regulatory Approval in Italy 1 page ?Kb
Regulatory Filings Classification · 95% confidence The document is a short announcement dated 3 January 2008 from Cyclopharm Limited regarding regulatory approval in Italy for their product Technegas. It mentions appointment of a distributor and sales terms but does not contain any financial statements, detailed financial data, or comprehensive report content. The length is only 1595 characters, which is quite short and typical of a regulatory or capital/market update. There is no indication of an annual or interim report, audit report, earnings release, or other detailed filings. The content focuses on regulatory approval and business expansion in a new market, which aligns with a Capital/Financing Update or Regulatory Filing. Since it is about regulatory approval and market expansion rather than financing or capital structure changes, the best fit is Regulatory Filings (RNS).
2008-01-02 English
Change of Director`s Interest Notice 2 pages ?Kb
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a director, including number of shares held before and after the change, nature of the change (on-market trades), and dates. There is no financial performance data, earnings information, or report publication. The content clearly matches the definition of a Director's Dealing report, which involves personal share transactions by company directors and executives (insider trades). The document length is short and focused solely on director share transactions, confirming it is not a broader financial or management report.
2007-10-15 English
Change of Director`s Interest Notice 2 pages ?Kb
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details a director's change in shareholding, including the number of shares disposed and held before and after the change. The content focuses on personal share transactions by a company director. The document length is 3155 characters, which is relatively short and specific to director dealings. This matches the definition of 'Director's Dealing' filings, which report personal share transactions by company directors and executives (insider trades).
2007-09-17 English
Half Yearly Report and Accounts 32 pages ?Kb
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Cyclopharm Limited Appendix 4D - Half Year Report' and covers the half year ended 30 June 2007. It includes detailed financial data such as revenues, losses, net tangible assets, and segment performance. It also contains a Managing Director's Review, Directors' Report, Income Statement, Balance Sheet, Cash Flow Statement, and Notes to the Financial Statements. The document length is 15,000 characters, indicating a comprehensive report rather than a brief announcement. The presence of actual financial statements and substantive financial analysis confirms it is a financial report for a period shorter than a full fiscal year. The reference to 'Appendix 4D' and half year reporting aligns with an Interim / Quarterly Report. Therefore, the document is best classified as an Interim / Quarterly Report (IR). H1 2007
2007-08-27 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.